MD MBA - Bicara Therapeutics Senior Affairs
| BCAX Stock | 16.74 0.85 4.83% |
Executive
MD MBA is Senior Affairs of Bicara Therapeutics Common
| Address | 116 Huntington Avenue, Boston, MA, United States, 02116 |
| Phone | 617 468 4219 |
| Web | https://www.bicara.com |
Bicara Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1859) % which means that it has lost $0.1859 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2664) %, meaning that it created substantial loss on money invested by shareholders. Bicara Therapeutics' management efficiency ratios could be used to measure how well Bicara Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -0.11 in 2026. Return On Capital Employed is likely to rise to -0.16 in 2026. At this time, Bicara Therapeutics' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 80.5 M in 2026, despite the fact that Return On Tangible Assets are likely to grow to (0.11).Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Carla Poulson | ProKidney Corp | N/A | |
| MPA MBA | Prime Medicine Common | 47 | |
| Pharm MPH | ProKidney Corp | N/A | |
| Sanjeev Narula | Phathom Pharmaceuticals | 65 | |
| Siddharth Advant | Savara Inc | N/A | |
| MPH MD | ProKidney Corp | N/A | |
| Stillman Hanson | Fortrea Holdings | N/A | |
| Stillman JD | Fortrea Holdings | N/A | |
| Timothy Redfern | Tango Therapeutics | 46 | |
| Bill JD | Phathom Pharmaceuticals | N/A | |
| Maeve MD | Tango Therapeutics | N/A | |
| Jannik Andersen | Tango Therapeutics | N/A | |
| Julie Carretero | Tango Therapeutics | 53 | |
| Dario MD | Eyepoint Pharmaceuticals | 67 | |
| JD CFA | Septerna Common Stock | 54 | |
| Mark Devlin | Phathom Pharmaceuticals | N/A | |
| William III | Maravai Lifesciences Holdings | 50 | |
| Anne Erickson | Savara Inc | 54 | |
| Agnieszka JD | Fortrea Holdings | 53 | |
| Kathleen Ford | Kura Oncology | 79 | |
| Braden Parker | Savara Inc | N/A | |
Management Performance
| Return On Equity | -0.27 | ||||
| Return On Asset | -0.19 |
Bicara Therapeutics Leadership Team
Elected by the shareholders, the Bicara Therapeutics' board of directors comprises two types of representatives: Bicara Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bicara. The board's role is to monitor Bicara Therapeutics' management team and ensure that shareholders' interests are well served. Bicara Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bicara Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD MBA, Senior Affairs | ||
| Angela Windt, VP Affairs | ||
| Lara JD, Chief Secretary | ||
| Ryan PharmD, COO President | ||
| Rachel Salazar, SVP Operations | ||
| Pauline Dufresne, Chief Officer | ||
| JeanPaul Rodrique, Senior Assurance | ||
| Sathish Hasige, Senior Chain | ||
| Gary MBA, VP Controller | ||
| Ivan MBA, Chief Officer | ||
| David MD, Chief Officer | ||
| Claire MBA, CEO Director |
Bicara Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bicara Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.27 | ||||
| Return On Asset | -0.19 | ||||
| Current Valuation | 628.86 M | ||||
| Shares Outstanding | 54.78 M | ||||
| Shares Owned By Insiders | 12.17 % | ||||
| Shares Owned By Institutions | 92.07 % | ||||
| Number Of Shares Shorted | 9.15 M | ||||
| Price To Book | 2.28 X | ||||
| EBITDA | (82.33 M) | ||||
| Net Income | (68 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Bicara Stock Analysis
When running Bicara Therapeutics' price analysis, check to measure Bicara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bicara Therapeutics is operating at the current time. Most of Bicara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Bicara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bicara Therapeutics' price. Additionally, you may evaluate how the addition of Bicara Therapeutics to your portfolios can decrease your overall portfolio volatility.